会社概要
- 正式社名: Transo-Pharm Handels GmbH
- 登録国: Germany
- 住所: Bueltbek 5, 22962 Siek
- 従業員数: 25 - 49
説明:
Transo-Pharm, founded in 1987, is a fully licensed global distributor of pharmaceutical components for health and veterinary industries. It supports customers throughout the API lifecycle, from development to sales, offering diverse products and qualifying manufacturers for compliance. Acting as a sourcing and regulatory marketing agent, Transo-Pharm has offices in Shanghai, Hong Kong, Singapore, the United States, and an affiliated office in Mumbai. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
事業活動
原薬(API)
販売代理店物流事業者薬事コンサルタント
ATC分類(解剖治療化学分類)
販売代理店物流事業者薬事コンサルタント
先発品原薬
販売代理店物流事業者薬事コンサルタント
薬事・市場調査サービス
サービスプロバイダー
主要製品/サービス
- 原薬(API): Hyoscine N-Butylbromide (CEP), Ajmaline (ASMF), Noscapine (ASMF), Scopolamine Hydrobromide (CEP / US-DMF), Scopolamine Methylbromide (US-DMF), Doxorubicin HCl (CEP), Epirubicin HCl ( CEP / US-DMF), Idarubicin HCl (ASMF / US-DMF), Nelarabine (US-DMF), Valrubicin (US-DMF), Epinephrine Base (CEP / US-DMF), Epinephrine Bitartrate (CEP / US-DMF), Estriol (CEP), Norepinephrine bitartrate (CEP / US-DMF), Thyroid Extract (USP), Dorzolamide HCl (CEP), Acetylcysteine (CEP), Crotamiton (CEP / US-DMF), Dexmedetomidine (ASMF), Guaifenesin (CEP / US-DMF), Hyoscine (CEP), Levosimendan (ASMF), Methocarbamol (ASMF / US-DMF), Nonivamide (ASMF), Phenylephrine HCl (CEP / US-DMF), Tranexamic Acid (CEP)
- 先発品原薬: Digoxin (CEP / US-DMF)
- 動物用医薬品・飼料添加物: Clenbuterol HCl (CEP / US-VMF)
当社の製品・サービス
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
認証
CEP証明書
DMF
GMP
証明
CPHI Milan 2026
10/2026 – 10/2026
CPHI Milan 2026
評価
(0)
(0)
(0)
(0)
(0)
コメント
フィルター:
並べ替え:
コメントはありません。
評価とコメントを残す